{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:59:52Z","timestamp":1785517192283,"version":"3.56.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"CORE project funded by Juntendo University Medical Technology Innovation Center"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00535-026-02419-z","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T09:21:11Z","timestamp":1777281671000},"page":"1083-1092","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immediate discontinuation versus gradual tapering of proton pump inhibitors in long-term users: a randomized controlled trial"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9671-5585","authenticated-orcid":false,"given":"Mariko","family":"Hojo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroya","family":"Ueyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Asaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryunosuke","family":"Okahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuko","family":"Nojiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyoshi","family":"Shibuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Nagahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"2419_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1083-4389.2004.00194.x","volume":"9","author":"H Miwa","year":"2004","unstructured":"Miwa H, Sakaki N, Sugano K, et al. Recurrent peptic ulcers in patients following successful Helicobacter pylori eradication: a multicenter study of 4940 patients. Helicobacter. 2004;9:9\u201316.","journal-title":"Helicobacter"},{"key":"2419_CR2","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/S0140-6736(09)60938-7","volume":"374","author":"P Malfertheiner","year":"2009","unstructured":"Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet. 2009;374:1449\u201361.","journal-title":"Lancet"},{"key":"2419_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/1756283X17705329","volume":"10","author":"K Iwakiri","year":"2017","unstructured":"Iwakiri K, Sakurai Y, Shiino M, et al. A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis. Therap Adv Gastroenterol. 2017;10:439\u201351.","journal-title":"Therap Adv Gastroenterol"},{"key":"2419_CR4","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1136\/gutjnl-2013-304722","volume":"63","author":"K Sugano","year":"2014","unstructured":"Sugano K, Choi MG, Lin JT, et al. Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study. Gut. 2014;63:1061\u20138.","journal-title":"Gut"},{"key":"2419_CR5","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1136\/gutjnl-2017-314010","volume":"67","author":"Y Mizokami","year":"2018","unstructured":"Mizokami Y, Oda K, Funao N, et al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut. 2018;67:1042\u201351.","journal-title":"Gut"},{"key":"2419_CR6","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1136\/gutjnl-2015-311304","volume":"65","author":"K Murakami","year":"2016","unstructured":"Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65:1439\u201346.","journal-title":"Gut"},{"key":"2419_CR7","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.2169\/internalmedicine.0492-17","volume":"57","author":"R Niikura","year":"2018","unstructured":"Niikura R, Yamada A, Hirata Y, et al. Efficacy of vonoprazan for gastroesophageal reflux symptoms in patients with proton pump inhibitor-resistant non-erosive reflux disease. Intern Med. 2018;57:2443\u201350.","journal-title":"Intern Med"},{"key":"2419_CR8","volume":"11","author":"MI Pinto-Sanchez","year":"2017","unstructured":"Pinto-Sanchez MI, Yuan Y, Hassan A, et al. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev. 2017;11:Cd011194.","journal-title":"Cochrane Database Syst Rev"},{"key":"2419_CR9","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1046\/j.1440-1746.2002.02783.x","volume":"17","author":"N Manabe","year":"2002","unstructured":"Manabe N, Yoshihara M, Sasaki A, et al. Clinical characteristics and natural history of patients with low-grade reflux esophagitis. J Gastroenterol Hepatol. 2002;17:949\u201354.","journal-title":"J Gastroenterol Hepatol"},{"issue":"Suppl 2","key":"2419_CR10","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/ajg.2009.44","volume":"104","author":"KL Insogna","year":"2009","unstructured":"Insogna KL. The effect of proton pump-inhibiting drugs on mineral metabolism. Am J Gastroenterol. 2009;104(Suppl 2):S2-4.","journal-title":"Am J Gastroenterol"},{"key":"2419_CR11","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/ajg.2011.113","volume":"106","author":"S Ngamruengphong","year":"2011","unstructured":"Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106:1209\u201318 (; quiz 1219).","journal-title":"Am J Gastroenterol"},{"key":"2419_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128004","volume":"10","author":"AA Lambert","year":"2015","unstructured":"Lambert AA, Lam JO, Paik JJ, et al. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS ONE. 2015;10:e0128004.","journal-title":"PLoS ONE"},{"key":"2419_CR13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.cgh.2011.09.030","volume":"10","author":"A Deshpande","year":"2012","unstructured":"Deshpande A, Pant C, Pasupuleti V, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:225\u201333.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2419_CR14","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gutjnl-2015-310861","volume":"65","author":"MA Jackson","year":"2016","unstructured":"Jackson MA, Goodrich JK, Maxan ME, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65:749\u201356.","journal-title":"Gut"},{"key":"2419_CR15","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","volume":"65","author":"F Imhann","year":"2016","unstructured":"Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65:740\u20138.","journal-title":"Gut"},{"key":"2419_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1053\/j.gastro.2009.03.058","volume":"137","author":"C Reimer","year":"2009","unstructured":"Reimer C, S\u00f8ndergaard B, Hilsted L, et al. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137:80\u20137, 87.e1.","journal-title":"Gastroenterology"},{"key":"2419_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/fampra\/cmu050","volume":"31","author":"P Haastrup","year":"2014","unstructured":"Haastrup P, Paulsen MS, Begtrup LM, et al. Strategies for discontinuation of proton pump inhibitors: a systematic review. Fam Pract. 2014;31:625\u201330.","journal-title":"Fam Pract"},{"key":"2419_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12876-021-02086-9","volume":"22","author":"M Hojo","year":"2022","unstructured":"Hojo M, Asaoka D, Shimada Y, et al. Strategies for discontinuation of proton pump inhibitors (PPIs) in patients with long-term PPI administration: a randomized controlled trial. BMC Gastroenterol. 2022;22:21.","journal-title":"BMC Gastroenterol"},{"key":"2419_CR19","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/175436","volume":"2015","author":"JE Zwisler","year":"2015","unstructured":"Zwisler JE, Jarb\u00f8l DE, Lassen AT, et al. Placebo-controlled discontinuation of long-term acid-suppressant therapy: a randomised trial in general practice. Int J Family Med. 2015;2015:175436.","journal-title":"Int J Family Med"},{"key":"2419_CR20","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","volume":"152","author":"DE Freedberg","year":"2017","unstructured":"Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152:706\u201315.","journal-title":"Gastroenterology"},{"key":"2419_CR21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0016-5085(99)70118-6","volume":"116","author":"D Gillen","year":"1999","unstructured":"Gillen D, Wirz AA, Ardill JE, et al. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology. 1999;116:239\u201347.","journal-title":"Gastroenterology"},{"key":"2419_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/ageing\/29.2.125","volume":"29","author":"R Fass","year":"2000","unstructured":"Fass R, Pulliam G, Johnson C. Symptom severity and oesophageal chemosensitivity to acid in older and young patients with gastro-oesophageal reflux. Age Ageing. 2000;29:125\u201330.","journal-title":"Age Ageing"},{"key":"2419_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12876-016-0448-x","volume":"16","author":"E Bayerd\u00f6rffer","year":"2016","unstructured":"Bayerd\u00f6rffer E, Bigard MA, Weiss W, et al. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease. BMC Gastroenterol. 2016;16:48.","journal-title":"BMC Gastroenterol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02419-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-026-02419-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02419-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:08:11Z","timestamp":1785514091000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-026-02419-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2419"],"URL":"https:\/\/doi.org\/10.1007\/s00535-026-02419-z","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"31 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Nagahara reports honoraria from Astellas Pharma Inc and Takeda Pharmaceutical Company Limited. Mariko Hojo, Kumiko Ueda, Hiroya Ueyama, Tsutomu Takeda, Shotaro Oki, Daiki Abe, Kei Nomura, Takashi Murakami, Dai Ishikawa, Daisuke Asaoka, Yuji Shimada, Ryunosuke Okahara, Shuko Nojiri, and Tomoyoshi Shibuya have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}